BioAssaix aims to provide a drug discovery platform for researchers to screen potential therapeutic entities such as natural product extracts and synthetic compounds. The need for novel and improved drugs for conditions such as diabetes, tuberculosis and cancer has fuelled an increase in the demand to identify compounds with suitable therapeutic and pharmacological properties. To this end BioAssaix screening services offers an array of target directed in vitro screening assays to identify new drug leads in a disease specific context, and provide an in vitro platform to quantitatively prioritise potential drug leads for further animal and clinical studies. In addition to providing an in vitro testing facility for anti-diabetic and anti-cancer drug development, we also offer other disease directed screening assays targeting TB, HIV and toxicity assessment. Screening services include a detailed screening report and possible option for further small scale custom designed mechanism based in vitro analysis on selected samples.

In the search for anti-diabetic therapies, selecting an appropriate animal model is challenging if the precise metabolic target is unknown. The multifactor nature of diabetes and the absence of any single animal model which encompasses the entire spectrum of human diabetes pose a dilemma in identifying the anti-diabetic activity as it is not possible to accurately select appropriate animal models and experimental designs without some knowledge of the mechanism through which these elicit a therapeutic effect. To address this problem BioAssiax offers a multi-target in vitro antidiabetic screening platform allowing researchers to prioritise test samples according to therapeutic target.